Clinical efficacy of Bambuterol alone and in combination with Borage & Echium seed oil in chronic persistent asthma

Author : Syed Saud Hasan, Moosa Khan, Musarrat Sultana, Asif Iqbal, Shamsul Arfin Qasmi

Introduction: Asthma chronic inflammatory disease, highly prevalent all ages, characterizes by cough, dyspnea, chest tightness, wheezing & impairment in physical activities. Inflammatory cells degranulation, release of numbers of mediators and toxic substances, leukotrieneís are consider important. Bambuterol, reducing the frequency of recurrent episodes of bronchospasm and Borage & Echium seed oil, inhibits the leukotrieneís generation & competing with the arachidonic acid, thus decreasing the inflammatory process. Objective: To evaluate the clinical efficacy of Bambuterol alone and in combination with Borage & Echium seed oil in chronic persistent asthma. Method & Materials: An interventional study, approved by BASR University of Karachi. Group-A, Bambuterol oral once daily & Group B, Bambuterol once daily & Borage seed oil 1.3 gram daily plus Echium seed oil 500mg twice daily for 90 days. Diagnosed 120-registered patients, 60 patients in each group completed study period, results compared by Spirometry, PEFR, daily symptoms diary card and clinical questionnaires evaluated statistically. Results: Group-A at day-90, percentage change of FEV1 4.7%, FVC 5.9%, PEFR 7.1%. Group-B, FEV1 13.3%, FVC 9.2%, PEFR 15.2%, results are statistically highly significant. Symptoms improvement and reduction in night sleep awakening, decreased need of recue medicine. Drug safety was determined by observing reported adverse effects on serum level of Alkaline Phosphatase, SGPT, Cholesterol, HDL, LDL and compliance of drug was checked by follow up at day-30, 60 & 90 and in between daily symptom dairy card. Conclusion: Improvement reported by mean of, reduced severity, improved clinical symptoms & quality of life and no serious adverse effects, results are highly significant. Combination therapy provided synergistic effect.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at